NCT07535307

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes

Effect of NNC0487-0111 on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to find out how NNC0487-0111 affects, how the body uses insulin (a hormone that helps the body control blood sugar) and how well the pancreas works in people living with type 2 diabetes. There are 2 study treatments. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	NNC0487-0111	NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.
DRUG	Placebo	Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to the abdomen.

Timeline

• Start date: 2026-04-10
• Primary completion: 2027-11-11
• Completion: 2027-12-06
• First posted: 2026-04-17
• Last updated: 2026-04-17

Locations

1 site across 1 country: Germany